← Back to Clinical Trials
Recruiting NCT07608055

NCT07608055 Clinical, Oncologic, and Metabolic Effects of Pancreatic Mass Loss After Pancreatectomy in Non-Diabetic Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07608055
Status Recruiting
Phase
Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Condition Pancreatectomy
Study Type OBSERVATIONAL
Enrollment 579 participants
Start Date 2026-07-20
Primary Completion 2037-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 579 participants in total. It began in 2026-07-20 with a primary completion date of 2037-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time. The study will include adults without diabetes before surgery who undergo pancreatic surgery as part of routine clinical care at Fondazione Policlinico Universitario A. Gemelli IRCCS. Researchers will study whether participants develop diabetes after surgery and whether this risk changes according to the type of pancreatic resection. Information from routine clinical care, metabolic tests, imaging, and pancreatic tissue samples collected during surgery may be used for research analyses.

Eligibility Criteria

Inclusion Criteria: * Adult patients (≥18 years) * No diabetes mellitus at baseline * Undergoing partial, near-total, or total pancreatectomy at the study center * Availability of clinical and metabolic data according to study component * Written informed consent for the prospective component Exclusion Criteria: * Diabetes mellitus at baseline * Age \<18 years * Missing key clinical data precluding eligibility assessment or primary outcome evaluation * Refusal or inability to provide informed consent for the prospective component, where applicable

Contact & Investigator

Central Contact

Teresa Mezza, MD, PhD

✉ teresa.mezza@policlinicogemelli.it

📞 06 30156664

Principal Investigator

Teresa Mezza

PRINCIPAL INVESTIGATOR

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Frequently Asked Questions

Who can join the NCT07608055 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07608055 currently recruiting?

Yes, NCT07608055 is actively recruiting participants. Contact the research team at teresa.mezza@policlinicogemelli.it for enrollment information.

Where is the NCT07608055 trial being conducted?

This trial is being conducted at Rome, Italy.

Who is sponsoring the NCT07608055 clinical trial?

NCT07608055 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Teresa Mezza at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 579 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology